Boston Scientific Highlights Trial Data For EkoSonic System For Pulmonary Embolism

Boston Scientific Corporation BSX announced results for the EkoSonic Endovascular System at the Vascular InterVentional Advances (VIVA) meeting.
Related: Boston Scientific Acquires Provider Of Thrombectomy Platform In Over $300M Deal.
The KNOCOUT PE registry was established to measure institutional adoption of a lower dose and lower-duration thrombolysis protocol for the EKOS system.
The data confirmed the safety and efficacy of the EKOS system for patients with intermediate-high and high-risk pulmonary embolism (PE).
The international registry of 489 patients included data from patients treated with the EKOS system, provided a lower drug dose and shorter infusion duration of a thrombolytic agent than administered in previous studies.
No intracerebral hemorrhagic events or brain bleeding events were observed.
A low major bleeding rate of 2.5%, compared to the rate previously observed with systemic thrombolysis treatment.
Results also demonstrated a 23% post-procedure reduction in the main indicator of heart strain from PE, measured as right ventricular to left ventricular diameter ratio (RV/LV).
Read Next: FDA Takes Note Of Higher Risk For Women With Stroke-Preventing Implants.
Price Action: BSX stock closed at $42.44 on Tuesday.

Overview Rating:

Speculative

100

0100